expand/collapse risk warning

CFDs come with a high risk of losing money rapidly due to leverage. 71% of accounts lose money when trading CFDs with this provider. You should understand how CFDs work and consider if you can take the risk of losing your money.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

71% of retail investor accounts lose money when trading CFDs with this provider.


Cellectis Stock

[[ data.name ]]

[[ data.ticker ]]

[[ data.price ]] [[ data.change ]] ([[ data.changePercent ]]%)

Low: [[ data.low ]]

High: [[ data.high ]]







Cellectis-ADR (CLLS.US) is a biotechnology company with a market capitalization of €111.93 million as of July 28, 2023. Founded in 1999 by André Choulika, it is headquartered in France and focuses on developing innovative gene-editing technologies. The company specializes in utilizing its proprietary technology, known as TALEN®, to engineer and modify genes for potential therapeutic applications.

It aims to address unmet medical needs and advance precision medicine through its cutting-edge gene-editing approaches. The company has forged strategic collaborations with various pharmaceutical companies to accelerate drug development. Cellectis went public in 2007 and has since made significant strides in the biotechnology sector, making notable advancements in the field of gene editing and establishing itself as a key player in the pursuit of revolutionary medical treatments.

Cellectis-ADR stock was first launched in 1999, and it has had a somewhat volatile history since then. In January 2021, the stock reached its highest price ever, hitting €28.45 per share. However, just a couple of years prior, in June 2018, the stock had hit a low of €1.61 per share, its lowest point in the past five years.

One interesting trend to note in the history of Cellectis-ADR stock is that it often experiences significant price jumps following news related to clinical trials, partnerships, or other collaborations. For example, in June 2018, the stock plunged after the announcement that a patient had died during a clinical trial related to a treatment being developed by the company.

So, how can traders and investors analyze the stock and make informed decisions about their trades? One popular strategy is to use technical indicators such as Bollinger Bands and moving averages to help identify trends and potential buy or sell signals.

As a trader or investor, you may be tempted to invest in this promising stock, but it is important to assess the market and keep an eye on alternative options. With that in mind, we have compiled the below competitors worth considering before you decide to invest in Cellectis-ADR stock:

  • Gilead Sciences (GILD.US): Gilead Sciences is a leading biopharmaceutical company with a diversified portfolio of products in the areas of HIV/AIDS, liver diseases, and oncology. The company is known for its strong pipeline of innovative products and for acquiring smaller biotech companies to fuel its growth.
  • Johnson & Johnson (JNJ.US): Johnson & Johnson is a diversified healthcare conglomerate that operates in three main segments: pharmaceuticals, medical devices, and consumer health. The company is known for its strong brand and stable financial performance.

Swap long [[ data.swapLong ]] points
Swap short [[ data.swapShort ]] points
Spread min [[ data.stats.minSpread ]]
Spread avg [[ data.stats.avgSpread ]]
Min contract size [[ data.minVolume ]]
Min step size [[ data.stepVolume ]]
Commission and Swap Commission and Swap
Leverage Leverage
Trading Hours Trading Hours

* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.

The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.

Trade [[data.name]] with Skilling

All Hassle-free, with flexible trade sizes and with zero commissions!*

  • Trade 24/5
  • Minimum margin requirements
  • No commission, only spread
  • Fractional shares available
  • Easy to use platform

*Other fees may apply.

Sign up

Why Trade [[data.name]]

Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.


Capitalise on rising prices (go long)


Capitalise on falling prices (go short)


Trade with leverage
Hold larger positions than the cash you have at your disposal


Trade on volatility
No need to own the asset


No commissions
Just low spreads


Manage risk with in-platform tools
Ability to set take profit and stop loss levels